1. Parkinson’s progression markers initiative
PPMI 2018 ANNUUAL INVESTIGATORS MEETING

2. PPMI Status Update

3. PPMI SITES IN AUSTRALIA:
PPMI SITES IN THE UNITED STATES:
Arizona PD Consortium (Sun City, AZ)
Beth Israel Medical Center (NY, NY)
Baylor College of Medicine (Houston, TX)
Boston University (Boston, MA)
Cleveland Clinic (Cleveland, OH)
Columbia University (NY, NY)
Emory University (Atlanta, GA)
Institute of Neurodegenerative Disorders (New Haven, CT)
Johns Hopkins University (Baltimore ,MD)
Northwestern University (Chicago, IL)
Oregon Health and Science University (Portland, OR)
The Parkinson’s Institute (Sunnyvale, CA)
PD & Movement Disorders Center at Boca Raton (Boca Raton, FL)
University of Alabama at Birmingham (Birmingham, AL)
University of California at San Diego (San Diego, CA)
University of California San Francisco
(San Francisco, CA)
University of Cincinnati (Cincinnati, OH)
University of Pennsylvania (Philadelphia, PA)
University of Rochester (Rochester, NY)
University of South Florida (Tampa, FL)
University of Washington (Seattle, WA)
PPMI SITES IN EUROPE:
Foundation for Biomedical Research of the Academy of Athens (Athens, Greece)
Imperial College (London, UK)
Innsbruck University (Innsbruck, Austria)
Norwegian University of Science and Technology (Trondheim, Norway)
Paracelsus-Elena Clinic Kassel/University of Marburg (Kassel and Marburg, Germany)
Pitié-Salpêtrière Hospital (Paris, France)
University of Barcelona (Barcelona, Spain)
University of Donostia (San Sebastien, Spain)
University of Salerno (Salerno, Italy)
University of Tübingen (Tübingen, Germany)
Kings College London (London, UK)
PPMI SITES IN AUSTRALIA:
Macquarie University (Sydney, Australia)
PPMI SITES IN Israel:
Tel Aviv Sourasky Medical Center (Tel Aviv, Israel)

4. Enrollment, retention and compliance

5. OVERVIEW Source of data for this presentation: Information comes from:
Tables produced for CSOC report
Tables produced for monthly review by steering committee
Additional data requests
All data comes from a data freeze based on data obtained from the LONI website on 04/02/2018.

6. PPMI ENROLLMENT
GROUP
Consented
Enrolled
Withdrawn
Active
Completed
PD Subjects
489
423 72
337 14
Healthy Controls
241
196 31
158 7
SWEDD Subjects 81 64 10 3 51
Prodromal - Hyposmic
119 26 4 22
Prodromal-RBD 96 39 36
LRRK2 PD Cohort
155
141 6
135
LRRK2 UA Cohort
190
180
SNCA PD Cohort 19 1 18
SNCA UA Cohort
GBA PD Cohort 77 73 70
GBA UA Cohort
129
126
TOTAL
1615
1306
143
1091

7. GENETIC COHORTS ENROLLMENT

8. VISIT COMPLIANCE
Group
6 Months # Exp (% Comp)
1 Year # Exp (% Comp)
2 Year # Exp (% Comp)
3 Year # Exp (% Comp)
4 Year # Exp (% Comp)
5 Year # Exp (% Comp) PD
414 (95%)
409 (96%)
399 (95%)
388 (94%)
377 (92%)
308 (87%) HC
192 (95%)
189 (98%)
181 (96%)
176 (95%)
172 (94%)
153 (88%)
SWEDD
62 (89%)
62 (94%)
61 (90%)
3 (33%)
3 (67%)
3 (100%)
Hyposmic
25 (96%)
24 (100%)
24 (96%)
20 (90%)
N/A
RBD
38 (97%)
38 (95%)
33 (91%)
4 (100%)
Genetic PD
205 (89%)
173 (90%)
115 (79%)
68 (87%)
2 (100%)
Genetic UA
250 (88%)
196 (93%)
84 (93%)
44 (84%)
6 (50%)
Number Expected = Number of active subjects within the milestone window
% Completed = Number of active subjects that completed the assessment within the milestone window

9. LUMBAR PUNCTURE COMPLETENESS
Group
Baseline # Exp (% Comp)
6 Months # Exp (% Comp)
1 Year #Exp (% Comp)
2 Year #Exp (% Comp)
3 Year #Exp (% Comp)
4 Year #Exp (% Comp)
5 Year #Exp (% Comp) PD
423 (98%)
392 (88%)
392 (84%)
378 (82%)
365 (78%)
346 (69%)
269 (62%) HC
196 (97%)
183 (87%)
185 (84%)
174 (79%)
167 (78%)
162 (67%)
135 (68%)
SWEDD
64 (92%)
55 (85%)
58 (83%)
55 (71%)
N/A
Hyposmic
23 (87%)
21 (76%)
21 (81%)
20 (60%)
17 (71%)
3 (67%)
RBD
38 (92%)
37 (81%)
37 (78%)
36 (67%)
30 (70%)
4 (25%)
Genetic PD
226 (84%)
155 (60%)
91 (65%)
59 (58%)
2 (100%)
Genetic UA
324 (88%)
182 (75%)
78 (68%)
37 (73%)
Number Expected = Number of active subjects with completed visit
% Completed = Number of active subjects that completed the assessment when they completed the visit

10. DATSCAN COMPLETENESS
Group
Baseline # Expected (% Comp)
1 Year #Expected (% Comp)
2 Year #Expected (% Comp)
4 Year #Expected (% Comp) PD
423 (99%)
392 (96%)
378 (93%)
346 (85%) HC
196 (91%)
N/A
SWEDD
64 (97%)
55 (96%)
Hyposmic
26 (100%)
24 (88%)
23 (91%)
RBD
39 (100%)
37 (97%)
36 (100%)
Genetic PD
231 (84%)
91 (81%)
2 (100%)
Genetic UA
324 (94%)
78 (87%)
3 (67%)
Number Expected = Number of active subjects with completed visit
% Completed = Number of active subjects that completed the assessment when they completed the visit

11. TIME TO START PD MEDS